Your browser doesn't support javascript.
The effect of favipiravir versus hydroxychloroquine on clinical and laboratory findings in COVID-19 in healthcare workers.
Turan, Derya Bayirli; Mentes, Mehtap; Özel, Yildiran; Serefhanoglu, Kivanç; Aydogan, Burcu; Ibil, Nese; Günesdogdu, Füsun; Orucova, Hijran Mammadova; Saltürk, Cüneyt; Çelik, Hakan.
  • Turan DB; Department of Infectious Diseases and Clinical Microbiology, Istanbul Yeni Yüzyil University Faculty of Medicine, Istanbul, Turkey. Electronic address: deryabturan@gmail.com.
  • Mentes M; Department of Occupational Health and Safety, Istanbul Yeni Yüzyil University Faculty of Medicine, Istanbul, Turkey.
  • Özel Y; Department of Occupational Health and Safety, Istanbul Yeni Yüzyil University Faculty of Medicine, Istanbul, Turkey.
  • Serefhanoglu K; Department of Infectious Diseases and Clinical Microbiology, Istanbul Yeni Yüzyil University Faculty of Medicine, Istanbul, Turkey.
  • Aydogan B; Department of Infection Control Committee, Istanbul Yeni Yüzyil University Faculty of Medicine, Istanbul, Turkey.
  • Ibil N; Department of Infection Control Committee, Istanbul Yeni Yüzyil University Faculty of Medicine, Istanbul, Turkey.
  • Günesdogdu F; Department of Family Medicine, Istanbul Yeni Yüzyil University Faculty of Medicine, Istanbul, Turkey.
  • Orucova HM; Department of Chest Diseases, Istanbul Yeni Yüzyil University Faculty of Medicine, Istanbul, Turkey.
  • Saltürk C; Department of Chest Diseases, Istanbul Yeni Yüzyil University Faculty of Medicine, Istanbul, Turkey.
  • Çelik H; Department of Pharmacology, Istanbul Yeni Yüzyil University Faculty of Medicine, Istanbul, Turkey.
Braz J Infect Dis ; 26(1): 102328, 2022.
Article in English | MEDLINE | ID: covidwho-1739570
ABSTRACT

OBJECTIVES:

Comparative data on hydroxychloroquine and favipiravir, commonly used agents in the treatment of Coronavirus Disease-2019 (COVID-19), are still limited. In this study, it was aimed to compare treatment outcomes in healthcare workers with COVID-19 who were prospectively followed by the occupational health and safety unit.

METHODS:

A total of 237 healthcare-workers, diagnosed as mild or moderate COVID-19 between March 11, 2020 and January 1, 2021, were given hydroxychloroquine (n = 114) or favipiravir (n = 123). Clinical and laboratory findings were evaluated.

RESULTS:

The mean age of the patients was 33.4±11.5 years. The mean time to negative PCR was found to be significantly shorter in patients receiving favipiravir compared to the hydroxychloroquine group (10.9 vs. 13.9 days; p < 0.001). The rate of hospitalization in the hydroxychloroquine group was significantly higher than favipiravir group (15.8% vs. 3.3%). In terms of side effects; the frequency of diarrhea in patients receiving hydroxychloroquine was significantly higher than that in the favipiravir group (31.6% vs. 6.5%; p < 0.001).

CONCLUSIONS:

Favipiravir and hydroxychloroquine were similar in terms of improvement of clinical symptoms of healthcare workers with mild or moderate COVID-19 infection, but favipiravir was significantly more effective in reducing viral load and hospitalization rates. Furthermore, favipiravir caused significantly less side-effects than hydroxychloroquine.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 Drug Treatment / Hydroxychloroquine Type of study: Experimental Studies / Prognostic study Limits: Adult / Humans / Young adult Language: English Journal: Braz J Infect Dis Journal subject: Communicable Diseases Year: 2022 Document Type: Article

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 Drug Treatment / Hydroxychloroquine Type of study: Experimental Studies / Prognostic study Limits: Adult / Humans / Young adult Language: English Journal: Braz J Infect Dis Journal subject: Communicable Diseases Year: 2022 Document Type: Article